Lenk, G. M. | Search bioRxiv

bioRxiv2026

CRISPR activation of PIKFYVE as potential therapy for FIG4 deficiency

Abstract/SummaryFIG4 deficiency is the cause of Charcot Marie Tooth type 4J, a neurological disorder characterized by enlarged lysosomes. Our CRISPR activation genome wide screen found that upregulation of PIKFYVE rescued the enlarged lysosome phenotype in cultured cells. To assess PIKFYVE upregulation treatment in vivo, we generated Fig4 deficient mice with CRISPR activation of Pikfyve in neurons. Pikfyve was increased 2 fold in whole brain of CRISPR activated mice. Pikfyve upregulation did not extend the 3 week survival of Fig4 deficient mice. Vacuolization of brain was not rescued. The data demonstrates that a 2 fold increase of Pikfyve is not sufficient to treat Fig4 deficiency. Further testing will be required to determine if a higher increase of Pikfyve can ameliorate the effects of FIG4 deficiency in vivo.

genetics↗

bioRxiv2024

Predictive modeling provides insight into the clinical heterogeneity associated with TARS1 loss-of-function mutations

Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed, essential enzymes that complete the first step of protein translation: ligation of amino acids to cognate tRNAs. Genes encoding ARSs have been implicated in myriad dominant and recessive phenotypes, the latter often affecting multiple tissues but with frequent involvement of the central and peripheral nervous system, liver, and lungs. Threonyl-tRNA synthetase (TARS1) encodes the enzyme that ligates threonine to tRNATHR in the cytoplasm. To date, TARS1 variants have been implicated in a recessive brittle hair phenotype. To better understand TARS1-related recessive phenotypes, we engineered three TARS1 missense mutations predicted to cause a loss-of-function effect and studied these variants in yeast and worm models. This revealed two loss-of-function mutations, including one hypomorphic allele (R433H). We next used R433H to study the effects of partial loss of TARS1 function in a compound heterozygous mouse model (R433H/null). This model presents with phenotypes reminiscent of patients with TARS1 variants and with distinct lung and skin defects. This study expands the potential clinical heterogeneity of TARS1-related recessive disease, which should guide future clinical and genetic evaluations of patient populations. SUMMARY STATEMENTThis study leverages an engineered, hypomorphic variant of threonyl-tRNA synthetase (TARS1) to capture TARS1-associated recessive phenotypes. This strategy revealed both known and previously unappreciated phenotypes, expanding the clinical heterogeneity associated with TARS1 and informing future genetic and clinical evaluations of patient populations.

genetics↗